Lennon RP, Demetriou TJ, Khalid MF, Van Scoy LJ, Miller EL, Dong H, Zgierska AE. Characteristics and outcomes among hospitalized COVID-19-positive patients in a nonurban environment. Mil Med. 2021 Nov 2;186(11-12):1088-92. doi: 10.1093/milmed/usab044
van der Wall SJ, Teutsch C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, Franca LR, Lu S, Lip GYH, Huisman MV, GLORIA-AF Investigators. Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF. TH Open. 2021 Feb 6;5(1):e35-42. doi: 10.1055/s-0040-1722706
van den Dries CJ, van Doorn S, Souverein P, Pajouheshnia R, Moons KGM, Hoes AW, Gerrsing G-J, van den Ham HA. The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation. TH Open. 2020 Dec 23;4(4):e417-26. doi: 10.1055/s-0040-1721499
Van Hout B, Hawe E, Cohen AT. Impact of patient characteristics on treatment outcomes in symptomatic venous thromboembolism: results of HOKUSAI-VTE randomized trial analysis. TH Open. 2020 Sep 23;4(3):e245-54. doi: 10.1055/s-0040-1716496
Skajaa N, Horvath-Puho E, Adelborg K, Prandoni P, Rothman KJ, Sorensen HT. Venous thromboembolism in Denmark: seasonality in occurrence and mortality. TH Open. 2019 Jun 18;3(2):e171-9. doi: 10.1055/s-0039-1692399.
Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol. 2008 Mar 1;126(3):345-52.
Offen W, Chuang-Stein C, Dmitrienko A, Copley-Merriman K. Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the PhRMA. Drug Inf J. 2007;4:31-46.
Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. Drug Inf J. 2000;34(4):1273-91.
Ciociola AA, Webb DD, McSorley DJ. The continued use of placebo-controlled clinical trials in the study of peptic ulcer disease: a sponsor perspective. Drug Inf J. 1996 Apr;30(2):433-9.
Doward LC. Developing a measure of quality of life for patients with recurrent genital herpes. Drug Inf J. 1994 Jan 1;28(1):19-25.
Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.